Epidermolysis bullosa House Austria as a role model for the care of a rare disease

Cover Page


Cite item

Full Text

Abstract

The evolution of the Epidermolysis bullosa (EB) House Austria in Salzburg has demonstrated from its beginning in 2005 in an exceptional way the establishment of an optimized health care for a hitherto neglected group of patients, suffering from a rare but devastating skin disease: Epidermolysis bullosa. Patients with this hereditary mechanobullous skin disease, characterized by a heterogenous clinical course, multisystemic manifestations and increased morbidity and mortality, find in the EB House Austria a multidisciplinary, medical and psychosocial, family-centered support, optimally customized to this condition and individualized to each patient. Its unique structure of four divisions (Outpatient Unit, Research Laboratory, Academy, Clinical Research and Study Center) has set the basis for the delivery of best medical practice and state-of-the-art care as well as the establishment/ performance of high quality and patient centered research and translational medicine. Initially the (ongoing) close collaboration with the powerful patient group and medical research charity “DEBRA Austria” that is dedicated to a multidimensional support of EB patients and their relatives living in Austria and neighboring countries, has enabled the construction of the EB House Austria. The acknowledgement of this institution as a successful model has been officially obtained in 2017 by its designation as a national Center of Expertise for Genodermatoses with special focus on EB and its inclusion into the European Reference Network (ERN) for Rare Skin Disorders in September 2018. Therefore, the history of the EB house is worth reviewing since it can be regarded as a role model for the care of other rare and multisystemic diseases.

About the authors

C. M. Prodinger

University Hospital of the Paracelsus Medical University of Salzburg

Author for correspondence.
Email: ch.prodinger@salk.at

Christine Maria Prodinger – MD, Department of Dermatology University Hospital of the Paracelsus Medical University of Salzburg, Department of Dermatology, Salzburger Landeskliniken (SALK), University Hospital of the Paracelsus Medical University

48 Muellner Hauptstrasse, Salzburg, 5020

Австрия

M. Laimer

University Hospital of the Paracelsus Medical University of Salzburg

Email: fake@neicon.ru

Martin Laimer – MD, Associate Professor, Department of Dermatology

48 Muellner Hauptstrasse, Salzburg, 5020

Австрия

J. Bauer

University Hospital of the Paracelsus Medical University of Salzburg

Email: fake@neicon.ru

Johann Bauer – MD, MBA, Professor, Department of Dermatology

48 Muellner Hauptstrasse, Salzburg, 5020

Австрия

H. Hintner

University Hospital of the Paracelsus Medical University of Salzburg

Email: fake@neicon.ru

Helmut Hintner – MD, Professor, Department of Dermatology

48 Muellner Hauptstrasse, Salzburg, 5020

Австрия

References

  1. Fine JD. Epidemiology of inherited epidermolysis bullosa. In: Fine JD, Hintner H, editors. Life with Epidermolysis Bullosa (EB): Etiology, diagnosis, multidisciplinary care and therapy. Wien, New York: Springer; 2008. p. 24–9.
  2. Fine JD, Bruckner-Tuderman L, Eady RA, Bauer EA, Bauer JW, Has C, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, Marinkovich MP, Martinez AE, McGrath JA, Mellerio JE, Moss C, Murrell DF, Shimizu H, Uitto J, Woodley D, Zambruno G. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103–26. doi: 10.1016/j.jaad.2014.01.903.
  3. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009;61(3):367–84. doi: 10.1016/j.jaad.2009.03.052.
  4. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009;61(3):387–402. doi: 10.1016/j.jaad.2009.03.053.
  5. Murrell DА, editor. Epidermolysis Bullosa: Part I – Pathogenesis and Clinical Features. Dermatol Clin. 2010;28(1):1–196.
  6. Lanschuetzer CM, Laimer M, Nischler E, Hintner H. Epidermolysis bullosa nevi. Dermatol Clin. 2010;28(1):179–83. doi: 10.1016/j.det.2009.10.024.
  7. Bauer JW, Schaeppi H, Kaserer C, Hantich B, Hintner H. Large melanocytic nevi in hereditary epidermolysis bullosa. J Am Acad Dermatol. 2001;44(4):577–84. doi: 10.1067/mjd.2001.112217.
  8. Laimer M, Prodinger C, Bauer JW. Hereditary epidermolysis bullosa. J Dtsch Dermatol Ges. 2015;13(11):1125–33. doi: 10.1111/ddg.12774.
  9. Nischler E, Klausegger A, Hüttner C, Pohla-Gubo G, Diem A, Bauer JW, Hintner H. Diagnostic pitfalls in newborns and babies with blisters and erosions. Dermatol Res Pract. 2009;2009:320403. doi: 10.1155/2009/320403.
  10. Yiasemides E, Walton J, Marr P, Villanueva EV, Murrell DF. A comparative study between transmission electron microscopy and immunofluorescence mapping in the diagnosis of epidermolysis bullosa. Am J Dermatopathol. 2006;28(5):387–94. doi: 10.1097/01.dad.0000211510.44865.6d.
  11. Hintner H, Stingl G, Schuler G, Fritsch P, Stanley J, Katz S, Wolff K. Immunofluorescence mapping of antigenic determinants within the dermal-epidermal junction in the mechanobullous diseases. J Invest Dermatol. 1981;76(2): 113–8. doi: 10.1111/1523-1747.ep12525447.
  12. Hintner H, Wolff K. Generalized atrophic benign epidermolysis bullosa. Arch Dermatol. 1982;118(6):375–84. doi: 10.1001/archderm.1982.01650180009008.
  13. Pohla-Gubo G, Kraus L, Hintner H. Role of immunofluorescence microscopy in dermatology. G Ital Dermatol Venereol. 2011;146(2): 127–42.
  14. Pohla-Gubo G, Cepeda-Valdes R, Hintner H. Immunofluorescence mapping for the diagnosis of epidermolysis bullosa. Dermatol Clin. 2010;28(2):201–10, vii. doi: 10.1016/j.det.2009.12.005.
  15. Pohla-Gubo G, Hintner H. Epidermolysis bullosa care in Austria and the Epidermolysis Bullosa House Austria. Dermatol Clin. 2010;28(2): 415–20, xv. doi: 10.1016/j.det.2010.02.008.
  16. Laimer M, Pohla-Gubo G, Diem A, Prodinger C, Bauer JW, Hintner H. Epidermolysis bullosa House Austria and Epidermolysis bullosa clinical network: Example of a centre of expertise implemented in a European reference network to face the burden of a rare disease. Wien Klin Wochenschr. 2017;129(1–2):1–7. doi: 10.1007/s00508-016-1133-3.
  17. Feramisco JD, Sadreyev RI, Murray ML, Grishin NV, Tsao H. Phenotypic and genotypic analyses of genetic skin disease through the Online Mendelian Inheritance in Man (OMIM) database. J Invest Dermatol. 2009;129(11): 2628–36. doi: 10.1038/jid.2009.108.
  18. EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States. October, 2011 [Accessed on 07/01/2019]. Available from: www.eucerd.eu.
  19. EUCERD Recommendations on Rare Disease European Reference Networks (RD ERNS). January, 2013 [Accessed on 07/01/2019]. Available from: www.eucerd.eu.
  20. EUCERD Recommendations on Core Indicators for Rare Disease National Plans/Strategies. June, 2013 [Accessed on 07/01/2019]. Available from: www.eucerd.eu.
  21. EUROPLAN Recommendations for the Development of National Plans for Rare Diseases. Guidance Document [Accessed on 07/01/2019]. Available from: www.europlanproject.eu.
  22. Directive on the application of patients’ rights in cross-border healthcare (2011/24/EU) March 9, 2011 [Accessed on 19/01/2019]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF.
  23. Laimer M, Prodinger C, Ahlgrimm-Siess V, Hintner H, Bauer JW. Austrian and European initiatives in the field of rare diseases perspectives for a "marginal group" of many millions of patients. J Dtsch Dermatol Ges. 2015;13(3):261–4. doi: 10.1111/ddg.12604.
  24. Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, Maruggi G, Ferrari G, Provasi E, Bonini C, Capurro S, Conti A, Magnoni C, Giannetti A, De Luca M. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12(12):1397–402. doi: 10.1038/nm1504.
  25. Bauer JW, Koller J, Murauer EM, De Rosa L, Enzo E, Carulli S, Bondanza S, Recchia A, Muss W, Diem A, Mayr E, Schlager P, Gratz IK, Pellegrini G, De Luca M. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J Invest Dermatol. 2017;137(3):778–81. doi: 10.1016/j.jid.2016.10.038.
  26. Siprashvili Z, Nguyen NT, Gorell ES, Loutit K, Khuu P, Furukawa LK, Lorenz HP, Leung TH, Keene DR, Rieger KE, Khavari P, Lane AT, Tang JY, Marinkovich MP. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA. 2016;316(17):1808–17. doi: 10.1001/jama.2016.15588.
  27. Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, Scaglione D, Reichelt J, Klausegger A, Kneisz D, Romano O, Secone Seconetti A, Contin R, Enzo E, Jurman I, Carulli S, Jacobsen F, Luecke T, Lehnhardt M, Fischer M, Kueckelhaus M, Quaglino D, Morgante M, Bicciato S, Bondanza S, De Luca M. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551(7680): 327–32. doi: 10.1038/nature24487.
  28. Wally V, Lettner T, Peking P, Peckl-Schmid D, Murauer EM, Hainzl S, Hintner H, Bauer JW. The pathogenetic role of IL-1β in severe epidermolysis bullosa simplex. J Invest Dermatol. 2013;133(7):1901–3. doi: 10.1038/jid.2013.31.
  29. Wally V, Kitzmueller S, Lagler F, Moder A, Hitzl W, Wolkersdorfer M, Hofbauer P, Felder TK, Dornauer M, Diem A, Eiler N, Bauer JW. Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study. Orphanet J Rare Dis. 2013;8:69. doi: 10.1186/1750-11728-69.
  30. Wally V, Hovnanian A, Ly J, Buckova H, Brunner V, Lettner T, Ablinger M, Felder TK, Hofbauer P, Wolkersdorfer M, Lagler FB, Hitzl W, Laimer M, Kitzmüller S, Diem A, Bauer JW. Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial. J Am Acad Dermatol. 2018;78(5):892–901.e7. doi: 10.1016/j.jaad.2018.01.019.
  31. EUCERD Working document: Minimal Data Set for Rare Diseases Registries. January, 2015 [Accessed on 07/01/2019]. Available from: http://www.eucerd.eu/wp-content/uploads//2015/03/WP8_Registries_MDS.pdf.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Prodinger C.M., Laimer M., Bauer J., Hintner H.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies